Stockscreener 앱 받기
4.25
3.63%
-0.16
시간 외 거래:
4.00
-0.25
-5.88%
전일 마감가:
$4.41
열려 있는:
$4.39
하루 거래량:
177.36K
Relative Volume:
0.50
시가총액:
$191.52M
수익:
$84.82M
순이익/손실:
$-21.43M
주가수익비율:
-8.6735
EPS:
-0.49
순현금흐름:
$-27.23M
1주 성능:
+0.47%
1개월 성능:
-6.39%
6개월 성능:
-71.85%
1년 성능:
-75.22%
1일 변동 폭
$4.235
$4.60
1주일 범위
$4.02
$4.60
52주 변동 폭
$3.84
$17.47
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
명칭
Y Mabs Therapeutics Inc
전화
646-885-8505
주소
202 CARNEGIE CENTER, PRINCETON, NY
YMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.25 | 191.52M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-18 | 개시 | Oppenheimer | Outperform |
| 2024-08-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 개시 | Truist | Buy |
| 2023-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-04-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-12-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-10-31 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-10-31 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재개 | Guggenheim | Buy |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-11-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-23 | 재개 | Cowen | Outperform |
| 2021-03-22 | 재개 | JP Morgan | Overweight |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-05-01 | 개시 | Janney | Buy |
| 2020-04-29 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 개시 | Wedbush | Outperform |
| 2019-04-01 | 개시 | H.C. Wainwright | Buy |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-10-16 | 개시 | BofA/Merrill | Buy |
모두보기
Y Mabs Therapeutics Inc 주식(YMAB)의 최신 뉴스
Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1% - Defense World
Legal & General Group Plc Decreases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline - Yahoo Finance
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price - simplywall.st
Y-mAbs Therapeutics (YMAB) Showcases CD38-SADA Data at AACR 2025 - GuruFocus
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Y-mAbs Therapeutics Presents Preclinical Data on CD38-SADA at 2025 AACR Annual Meeting - Nasdaq
Revolutionary Cancer Treatment: Y-mAbs CD38-SADA Therapy Achieves 20X Faster Clearance Rate in Latest Trial - Stock Titan
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $6.44 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Q1 EPS Forecast for Y-mAbs Therapeutics Reduced by Analyst - Defense World
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment - Investing.com
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment By Investing.com - Investing.com India
Y-mAbs Therapeutics (YMAB) Begins Phase 1 Trial for Non-Hodgkin - GuruFocus
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - The Manila Times
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform - TipRanks
Y-mAbs Therapeutics Initiates Phase 1 Trial of CD38-SADA Pre-targeted Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma - Nasdaq
Groundbreaking Radioimmunotherapy: Y-mAbs Launches First-in-Human Trial for Advanced Lymphoma Treatment - Stock Titan
When the Price of (YMAB) Talks, People Listen - news.stocktradersdaily.com
Y-mAbs (YMAB) Faces Downgrade as Market Potential Wanes - GuruFocus
Y-mAbs drops as Bank of America downgrades on headwinds to Danyelza - MSN
ITeos Therapeutics Inc (ITOS) Stock: From Low to High in 52 Weeks - investchronicle.com
Y-Mabs Therapeutics Inc Inc. (YMAB) Price Performance: The Role of Supply and Demand - investchronicle.com
Y-Mabs Therapeutics Inc (YMAB) stock: A year of ups and downs - uspostnews.com
Ratio Review: Analyzing Y-Mabs Therapeutics Inc (YMAB)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Bank of America to “Underperform” - Defense World
Y-mAbs stock down as Bank of America downgrades (YMAB:NASDAQ) - Seeking Alpha
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update - Defense World
Vanguard Group Inc. Trims Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Wellington Management Group LLP Sells 3,451 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
ExodusPoint Capital Management LP Buys New Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - The AM Reporter
KLP Kapitalforvaltning AS Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Prudential Financial Inc. Lowers Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity (YMAB) - Seeking Alpha
Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation - openPR.com
YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire
Pediatric Neuroblastoma Treatment Market Size in 7MM - openPR.com
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Refractory Metastatic Melanoma Clinical and Non-Clinical - openPR.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Boosted by Charles Schwab Investment Management Inc. - Defense World
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Top Premarket Decliners - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
HC Wainwright Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views - Benzinga
Learn to Evaluate (YMAB) using the Charts - news.stocktradersdaily.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock - Investing.com India
Y Mabs Therapeutics Inc (YMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Y Mabs Therapeutics Inc 주식 (YMAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
0.39%
3.66%
자본화:
|
볼륨(24시간):